Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 6,000 Shares of United Therapeutics Corporation $UTHR

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 20.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 35,100 shares of the biotechnology company’s stock after acquiring an additional 6,000 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in United Therapeutics were worth $10,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Rossby Financial LCC grew its holdings in shares of United Therapeutics by 38.3% in the second quarter. Rossby Financial LCC now owns 1,803 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 499 shares during the period. AustralianSuper Pty Ltd grew its holdings in shares of United Therapeutics by 1.8% in the second quarter. AustralianSuper Pty Ltd now owns 287,845 shares of the biotechnology company’s stock worth $82,712,000 after acquiring an additional 5,106 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of United Therapeutics by 2.9% in the second quarter. Teacher Retirement System of Texas now owns 11,941 shares of the biotechnology company’s stock worth $3,431,000 after acquiring an additional 339 shares during the period. Y Intercept Hong Kong Ltd grew its holdings in shares of United Therapeutics by 316.7% in the second quarter. Y Intercept Hong Kong Ltd now owns 17,315 shares of the biotechnology company’s stock worth $4,975,000 after acquiring an additional 13,160 shares during the period. Finally, Ashton Thomas Private Wealth LLC grew its holdings in shares of United Therapeutics by 112.8% in the second quarter. Ashton Thomas Private Wealth LLC now owns 9,925 shares of the biotechnology company’s stock worth $2,852,000 after acquiring an additional 5,261 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 1.4%

NASDAQ:UTHR opened at $415.34 on Wednesday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $459.48. The stock has a 50-day moving average price of $401.57 and a 200 day moving average price of $334.83. The stock has a market capitalization of $18.74 billion, a P/E ratio of 16.21, a P/E/G ratio of 4.59 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter in the prior year, the business posted $5.85 EPS. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. On average, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 4,000 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $424.06, for a total transaction of $1,696,240.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $55,127.80. This trade represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $417.50, for a total value of $9,393,750.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 349,435 shares of company stock worth $144,451,272. 10.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

UTHR has been the subject of several recent research reports. Bank of America boosted their price target on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Oppenheimer upped their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. JPMorgan Chase & Co. reduced their price target on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. UBS Group upped their price target on United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research report on Monday, September 29th. Finally, Cantor Fitzgerald upped their price target on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $461.62.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.